Ser9
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser9  -  GSK3B (human)

Site Information
SGRPRttsFAEsCkP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449111

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 448 , 468 ) , electrophoretic mobility shift ( 457 ) , flow cytometry ( 3 , 22 ) , immunoprecipitation ( 3 , 6 , 10 , 12 , 16 , 22 , 26 , 32 , 207 , 237 , 292 , 315 , 449 ) , mass spectrometry ( 10 , 13 , 16 , 29 , 30 , 37 , 45 , 46 , 50 , 52 , 53 , 55 , 57 , 58 , 61 , 63 , 64 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 95 , 96 , 97 , 100 , 101 , 102 , 103 , 104 , 105 , 115 , 116 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 226 , 228 , 229 , 235 , 245 , 246 , 247 , 248 , 249 , 250 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 290 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 312 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 338 , 339 , 340 , 341 , 343 , 344 , 346 , 352 , 353 , 366 ) , microscopy-colocalization with upstream kinase ( 347 , 396 ) , modification-specific antibody ( 10 , 34 ) , mutation of modification site ( 3 , 9 , 10 , 14 , 22 , 26 , 30 , 49 , 110 , 134 , 206 , 236 , 314 , 357 , 364 , 367 , 405 , 432 , 444 , 468 ) , peptide sequencing ( 40 , 225 ) , phospho-antibody ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 30 , 31 , 32 , 33 , 34 , 35 , 38 , 39 , 42 , 49 , 51 , 60 , 62 , 65 , 94 , 99 , 107 , 108 , 109 , 110 , 111 , 114 , 117 , 118 , 119 , 133 , 134 , 135 , 166 , 195 , 206 , 207 , 223 , 227 , 230 , 231 , 232 , 233 , 234 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 251 , 265 , 289 , 292 , 301 , 310 , 313 , 314 , 315 , 316 , 325 , 335 , 336 , 337 , 342 , 345 , 346 , 347 , 350 , 351 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 367 , 368 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 411 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 421 , 422 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 437 , 438 , 439 , 441 , 442 , 443 , 444 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 454 , 455 , 456 , 457 , 458 , 459 , 461 , 462 , 463 , 464 , 465 , 466 , 469 ) , phosphoamino acid analysis ( 85 ) , phosphopeptide mapping ( 468 ) , western blotting ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 30 , 31 , 32 , 33 , 34 , 35 , 38 , 39 , 42 , 49 , 51 , 60 , 62 , 85 , 94 , 99 , 107 , 108 , 109 , 110 , 111 , 114 , 117 , 118 , 119 , 133 , 134 , 135 , 166 , 195 , 206 , 207 , 223 , 225 , 227 , 230 , 231 , 232 , 233 , 234 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 265 , 289 , 292 , 301 , 310 , 313 , 314 , 315 , 316 , 325 , 335 , 336 , 337 , 342 , 345 , 346 , 347 , 350 , 351 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 364 , 365 , 367 , 368 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 382 , 384 , 385 , 386 , 387 , 388 , 390 , 392 , 395 , 396 , 403 , 404 , 406 , 411 , 413 , 414 , 415 , 421 , 422 , 423 , 424 , 425 , 426 , 428 , 431 , 432 , 434 , 435 , 437 , 438 , 442 , 443 , 444 , 446 , 449 , 450 , 451 , 452 , 454 , 455 , 458 , 461 , 465 , 466 , 469 )
Disease tissue studied:
bipolar disprder ( 8 ) , adrenal cancer ( 16 , 390 , 421 ) , pheochromocytoma ( 16 , 390 , 421 ) , bone cancer ( 18 , 230 , 357 ) , brain cancer ( 114 , 223 , 230 , 231 , 342 , 355 , 373 , 385 , 395 , 469 ) , glioblastoma ( 114 , 230 , 342 , 373 , 385 , 395 ) , glioblastoma multiforme ( 223 , 385 ) , glioma ( 114 , 223 , 230 , 342 , 373 , 385 , 395 ) , medulloblastoma ( 231 ) , Schwannoma ( 469 ) , breast cancer ( 10 , 14 , 27 , 53 , 55 , 207 , 225 , 230 , 313 , 347 , 364 , 374 , 383 , 404 , 406 , 415 , 418 , 431 , 446 , 450 ) , HER2 positive breast cancer ( 13 ) , luminal A breast cancer ( 13 ) , luminal B breast cancer ( 13 ) , breast cancer, surrounding tissue ( 13 ) , breast cancer, triple negative ( 13 ) , colorectal cancer ( 3 , 17 , 18 , 60 , 275 , 335 , 346 , 366 , 414 ) , colorectal carcinoma ( 3 , 17 , 18 , 60 , 335 , 346 , 366 , 414 ) , endometrial cancer ( 4 , 240 ) , endometrial adenocarcinoma ( 4 , 240 ) , gastric cancer ( 101 , 102 , 103 , 104 , 105 , 115 , 116 , 235 , 236 , 292 , 350 , 356 ) , gastric carcinoma ( 101 , 102 , 103 , 104 , 105 , 115 , 116 , 235 , 236 , 292 , 350 , 356 ) , kidney cancer ( 49 ) , leukemia ( 12 , 190 , 191 , 192 , 193 , 194 , 233 , 237 , 358 , 383 ) , acute myelogenous leukemia ( 237 , 358 , 383 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 237 , 383 ) , chronic myelogenous leukemia ( 7 , 190 , 191 , 192 , 193 , 194 , 233 ) , liver cancer ( 20 , 25 , 111 , 374 , 376 , 437 ) , liver adenocarcinoma ( 25 ) , lung cancer ( 47 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 208 , 230 , 235 , 251 , 263 , 335 , 364 , 366 , 426 ) , mesothelioma ( 122 ) , non-small cell lung cancer ( 47 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 208 , 251 , 335 , 364 ) , non-small cell lung adenocarcinoma ( 47 , 120 , 123 , 124 , 125 , 126 , 127 , 128 , 235 ) , non-small cell squamous cell lung carcinoma ( 121 , 122 , 129 , 235 , 263 , 335 ) , lymphoma ( 9 , 38 , 234 , 237 , 310 , 378 , 383 ) , B cell lymphoma ( 9 , 378 ) , Burkitt's lymphoma ( 378 ) , non-Hodgkin's lymphoma ( 9 ) , mantle cell lymphoma ( 9 ) , PEL ( 38 ) , neuroblastoma ( 5 , 16 , 24 , 28 , 29 , 52 , 107 , 119 , 135 , 200 , 201 , 202 , 203 , 204 , 315 , 351 , 355 , 375 , 421 , 442 , 454 ) , ovarian cancer ( 17 , 18 , 420 , 446 ) , pancreatic cancer ( 15 , 18 , 23 , 110 , 207 , 403 , 411 ) , pancreatic carcinoma ( 15 , 18 , 23 , 207 , 403 , 411 ) , pancreatic ductal adenocarcinoma ( 45 ) , prostate cancer ( 31 , 32 , 238 , 264 , 336 , 379 , 413 , 425 , 465 ) , melanoma skin cancer ( 6 , 239 , 386 ) , fibrosarcoma of soft tissue ( 455 ) , thyroid cancer ( 380 ) , schizophrenia ( 428 ) , sporadic inclusion-body myositis ( 232 )
Relevant cell line - cell type - tissue:
'brain, cerebellum' ( 231 ) , 'brain, cerebral cortex' ( 21 , 424 , 428 ) , 'brain, cerebral cortex' [Akt3 (mouse), no information] ( 42 ) , 'brain, hippocampus' ( 8 , 393 ) , 'brain, striatum' ( 393 ) , 'macrophage, alveolar'-lung ( 462 ) , 'muscle, skeletal' ( 118 , 232 , 337 , 345 , 391 , 397 ) , 'muscle, smooth'-'heart, artery' ( 206 ) , 'neuron, cerebellar granule'-brain ( 400 ) , 'neuron, cortical'-brain ( 393 ) , 'neuron, dorsal root ganglion'-brain ( 450 ) , 'neuron, hippocampal'-brain ( 393 ) , 'pancreatic, ductal'-pancreas ( 45 ) , 'stem, embryonic' ( 62 ) , 'stem, induced pluripotent' ( 8 , 65 ) , 21T (breast cell) ( 207 ) , 22Rv1 (prostate cell) ( 422 ) , 293 (epithelial) ( 3 , 22 , 26 , 30 , 68 , 69 , 70 , 71 , 72 , 134 , 230 , 361 , 367 , 372 , 377 , 378 , 382 , 390 , 409 , 418 , 425 , 429 , 430 , 438 , 449 , 461 , 464 , 466 ) , 293T (epithelial) ( 207 , 241 , 314 , 364 , 405 , 406 , 433 , 451 ) , 3T3 (fibroblast) ( 30 , 387 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 399 , 427 , 464 ) , 786-O (renal) ( 49 ) , A172 (glial) ( 401 ) , A2780 (ovarian) ( 18 ) , A375 (melanocyte) ( 239 ) , A549 (pulmonary) ( 47 , 230 , 335 , 366 , 426 ) , A7r5 ('muscle, smooth') ( 206 ) , ACN ( 24 ) , agranulocyte-blood ( 368 ) , AGS (gastric) ( 292 , 356 ) , AGS (gastric) [CCKBR (human), transfection] ( 236 ) , Aspc1 (pancreatic) ( 15 , 18 , 23 ) , B lymphocyte ( 378 ) , BAEC (endothelial) ( 365 ) , BC3 (B lymphocyte) ( 38 ) , Ben-Men-1 ( 469 ) , BeWo ( 265 ) , BeWo31 ( 265 ) , BJAB (B lymphocyte) ( 378 ) , breast ( 10 , 13 ) , BT-20 (breast cell) ( 55 ) , BT-474 (breast cell) ( 364 , 406 ) , BT-549 (breast cell) ( 55 ) , C4-2 (prostate cell) ( 238 , 422 ) , Calu-3 (pulmonary) ( 128 ) , CFPAC-1 (pancreatic) ( 362 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 466 ) , CHO (fibroblast) [EPOR (human)] ( 367 ) , chromaffin-adrenal gland ( 301 ) , colon ( 275 ) , COS (fibroblast) ( 370 , 382 , 392 , 396 , 443 , 450 ) , Daoy ( 231 ) , DM4 (melanocyte) ( 239 ) , DU 145 (prostate cell) ( 32 , 336 , 422 , 465 ) , DV-90 (pulmonary) ( 126 ) , endothelial-aorta ( 388 ) , endothelial-vein ( 444 ) , epithelial-lens ( 166 ) , erythroblast-spleen ( 456 ) , ES (stem) ( 390 ) , fibroblast-foreskin ( 426 ) , FTC-133 (thyroid cell) ( 408 ) , GI-101A (breast cell) ( 446 ) , GRANTA-519 (B lymphocyte) ( 9 ) , H19-7 (neuron) [IGF1R (human)] ( 401 ) , HaCaT (keratinocyte) ( 435 , 459 ) , HCC1937 (breast cell) ( 55 ) , HCEC (epithelial) ( 244 ) , HCN-2 ('neuron, cortical') ( 243 ) , HCT116 (intestinal) ( 3 , 17 , 60 , 255 , 335 , 346 , 366 , 414 ) , HEI-193 (Schwann) ( 469 ) , HeLa (cervical) ( 10 , 37 , 39 , 47 , 108 , 227 , 242 , 245 , 246 , 247 , 248 , 249 , 250 , 288 , 344 , 362 , 367 , 376 , 441 ) , HeLa S3 (cervical) ( 343 , 468 ) , HeLa_Meta (cervical) ( 205 ) , HeLa_Pro (cervical) ( 205 ) , HeLa_Telo (cervical) ( 205 ) , Hep3B (hepatic) ( 398 ) , hepatocyte-liver ( 289 ) , HepG2 (hepatic) ( 20 , 111 , 254 , 374 , 376 , 398 , 416 , 437 , 447 ) , HEY (ovarian) ( 446 ) , HL60 (myeloid) ( 12 , 237 ) , HN5 (squamous) ( 407 ) , Hs 578T (breast cell) ( 364 ) , HS294T (melanocyte) ( 239 ) , HT-29 (intestinal) ( 405 ) , HT1080 (fibroblast) ( 427 , 463 ) , HUVEC (endothelial) ( 325 , 371 , 426 , 452 ) , IGROV1 (ovarian) ( 439 ) , IMR-90 (fibroblast) ( 110 ) , IOSE-29 (ovarian) ( 439 ) , Ishikawa (endometrial) ( 240 ) , JAR (placental) ( 133 ) , JB (epithelial) ( 423 ) , JEKO-1 (B lymphocyte) ( 9 ) , Jurkat (T lymphocyte) ( 46 , 61 , 63 , 64 , 77 , 78 , 79 , 80 , 81 , 82 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 95 , 96 , 97 , 99 , 100 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 196 , 197 , 198 , 199 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 226 , 228 , 229 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 290 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 312 , 352 , 353 , 366 , 402 , 417 ) , K562 (erythroid) ( 50 , 190 , 191 , 192 , 193 , 194 , 233 ) , KG-1 (myeloid) ( 237 , 383 ) , KLE (endometrial) ( 4 ) , L02 (hepatic) ( 35 , 85 ) , L6 (myoblast) ( 397 ) , LAN-1 (neural crest) ( 315 ) , LAN-6 (neural crest) ( 29 , 200 , 201 ) , LAPC-4 (prostate cell) ( 422 ) , liver ( 289 ) , LN-Z308 (glial) ( 373 ) , LN229 (glial) ( 385 ) , LNCaP (prostate cell) ( 31 , 32 , 264 , 379 , 422 , 425 , 465 ) , LOU-NH91 (squamous) ( 121 ) , lung ( 40 , 263 ) , lymph node ( 234 ) , lymphocyte ( 428 ) , lymphocyte-blood ( 7 ) , M14-MEL (melanocyte) ( 6 , 386 ) , macrophage-bone marrow ( 11 ) , MC3T3 (preosteoblast) ( 448 ) , MCF-10A (breast cell) ( 27 , 446 ) , MCF-7 (breast cell) ( 14 , 55 , 230 , 313 , 362 , 364 , 374 , 383 , 415 , 418 ) , MCF-7 (breast cell) [CYP19A1 (human)] ( 404 ) , MCF12A (epithelial) ( 10 ) , MDA-MB-231 (breast cell) ( 10 , 55 , 313 , 364 , 415 , 450 ) , MDA-MB-435 (breast cell) ( 362 ) , MDA-MB-453 (breast cell) ( 362 ) , MDA-MB-468 (breast cell) ( 55 , 225 ) , MDAH2774 (ovarian) ( 362 ) , MEF (fibroblast) ( 17 , 357 ) , MEF (fibroblast) [Akt1 (mouse), homozygous knockout] ( 94 ) , MEF (fibroblast) [Etk (human), heterozygous knockout] ( 51 ) , MEF (fibroblast) [Myc (mouse)] ( 386 ) , MEL624 (melanocyte) ( 239 ) , mesangial ( 117 ) , MeWo (melanocyte) ( 239 ) , microvessel endothelial ( 195 , 316 ) , MKN-45 (gastric) ( 101 , 102 , 103 , 104 , 105 , 115 , 116 , 235 , 330 , 331 , 332 , 333 , 334 , 338 , 339 , 356 ) , MKN-74 (gastric) ( 292 ) , MSN (neuron) ( 419 ) , MV4-11 (macrophage) ( 255 ) , myoblast ( 363 ) , NA (squamous) ( 394 ) , NB-4 (myeloid) ( 383 ) , NB10 (neural crest) ( 52 ) , NCI-H1299 (pulmonary) ( 335 ) , NCI-H157 (pulmonary) ( 364 , 405 ) , NCI-H1650 (pulmonary) ( 125 , 208 , 335 ) , NCI-H1703 (squamous) ( 235 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 326 , 327 , 328 , 329 , 335 , 340 , 341 ) , NCI-H1975 (pulmonary) ( 124 ) , NCI-H2073 (pulmonary) ( 120 ) , NCI-H2170 (squamous) ( 129 ) , NCI-H226 (pulmonary) ( 122 ) , NCI-H23 (pulmonary) ( 335 ) , NCI-H2342 (pulmonary) ( 127 ) , NCI-H3255 (pulmonary) ( 235 , 252 , 253 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 ) , NCI-H441 (pulmonary) ( 123 ) , NCI-H460 (pulmonary) ( 251 , 335 ) , neuron-'brain, cerebellum' ( 421 ) , neuron-'brain, hippocampus' ( 442 ) , neutrophil ( 458 ) , NPC (neural crest) ( 52 ) , OK (renal) ( 360 ) , ovary ( 420 ) , OVCAR3 (ovarian) ( 362 ) , OVCAR4 (ovarian) ( 420 ) , OVCAR5 (ovarian) ( 420 ) , PANC-1 (pancreatic) ( 15 , 207 , 403 ) , pancreas ( 15 , 411 ) , pancreatic ( 110 ) , PC-12 (chromaffin) ( 16 , 390 , 401 , 421 ) , PC3 (prostate cell) ( 31 , 32 , 238 , 336 , 413 , 422 , 432 , 465 ) , QZG (hepatic) ( 85 ) , Raji (B lymphocyte) ( 378 ) , Rat1 (fibroblast) ( 464 ) , Saos-2 (bone cell) ( 448 ) , SB2 (melanocyte) ( 239 ) , Schwann ( 314 ) , SH-SY5Y (neural crest) ( 5 , 16 , 28 , 29 , 107 , 135 , 203 , 204 , 351 , 375 , 389 , 401 , 421 , 430 , 442 , 454 , 457 ) , SHEP (neuron) ( 419 ) , SK-HEP-1 (endothelial) ( 25 ) , SK-MEL2 (melanocyte) ( 239 ) , SK-MEL28 (melanocyte) ( 19 ) , SK-MEL5 (melanocyte) ( 239 ) , SK-N-MC (neural crest) ( 119 , 419 ) , SKBr3 (breast cell) ( 53 , 347 , 362 , 364 , 431 ) , skin ( 239 ) , SKNBE(2) (neural crest) ( 5 , 29 ) , SKNSH (neural crest) ( 16 ) , SKOV-3 (ovarian) ( 17 , 420 , 439 ) , SMMC7721 (hepatocyte) ( 25 ) , SMS-KCN-A (neural crest) ( 29 , 202 ) , SNB-19 (glial) ( 385 , 395 ) , SNU-1 (gastric) ( 356 ) , SNU-484 (gastric) ( 350 ) , SNU-620 (gastric) ( 350 ) , SNU16Ad (gastric) ( 292 ) , spermatozoa ( 34 ) , Su.86.86 (pancreatic) ( 15 ) , SUM159 (breast cell) ( 14 ) , SW480 (intestinal) ( 3 ) , SW620 (intestinal) ( 18 ) , Swiss 3T3 (fibroblast) ( 451 ) , synoviocyte-synovium ( 354 ) , T lymphocyte-blood ( 58 , 109 , 354 ) , T47D (breast cell) ( 347 , 362 ) , TF-1 (erythroid) ( 383 ) , THP1 (myeloid) ( 358 ) , TT (thyroid cell) ( 380 ) , U-937 (myeloid) ( 237 , 310 , 383 ) , U251 (glial) ( 342 , 373 , 385 , 395 ) , U2OS (bone cell) ( 18 , 230 , 357 ) , U373 MG (glial) ( 223 , 385 ) , U87MG (glial) ( 114 , 230 , 385 , 395 ) , UACC-257 (melanocyte) ( 239 ) , UCSD-354L (melanocyte) ( 239 ) , vascular smooth muscle cell ('muscle, smooth') ( 359 ) , WEHI-164 (fibroblast) ( 455 ) , WEHI-231 (B lymphocyte) ( 378 ) , WI-38 (fibroblast) ( 427 ) , WM-1552 (melanocyte) ( 239 ) , WM115 (melanocyte) ( 287 ) , WM1799 (melanocyte) ( 239 ) , WM2664 (melanocyte) ( 239 ) , WM3211 (melanocyte) ( 239 ) , WM35 (melanocyte) ( 239 ) , WM46 (melanocyte) ( 239 ) , ZR-75-1 (breast cell) ( 364 , 374 )

Upstream Regulation
Regulatory protein:
5-HT(1A) (human) ( 206 ) , Akt1 (cow) ( 445 ) , Akt1 (human) ( 62 , 110 , 360 , 364 , 371 , 414 ) , Akt2 (human) ( 364 ) , Akt3 (human) ( 42 , 364 ) , AurA (human) ( 292 ) , BAP28 (human) ( 15 ) , BMP4 (human) ( 206 ) , BRAF (human) ( 239 ) , CHKA (human) ( 313 ) , CHKB (human) ( 313 ) , CYR61 (human) ( 223 ) , DARPP-32 (human) ( 356 ) , DDIT4 (human) ( 409 ) , DDIT4L (human) ( 409 ) , Diaphanous-1 (mouse) ( 370 ) , Diaphanous-2 (mouse) ( 370 ) , DKK1 (human) ( 117 ) , E4 (adenovirus) ( 426 ) , EDG4 (human) ( 451 ) , EDG7 (human) ( 451 ) , EDN1 (human) ( 206 ) , FKBP5 (human) ( 4 ) , FSTL1 (mouse) ( 325 ) , GSK3B (human) ( 32 , 362 ) , HRas (human) ( 110 ) , IEX-1 (human) ( 367 ) , IKKB (human) ( 345 ) , ILK (human) ( 403 , 425 , 438 , 465 ) , ILKAP (human) ( 425 , 461 ) , ITGB1 (mouse) ( 291 ) , KIF1B (human) ( 16 ) , LAPTM4B (human) ( 31 ) , LKB1 (human) ( 335 ) , LPAR1 (human) ( 451 ) , LPIN1 (mouse) ( 289 ) , LRPAP1 (human) ( 310 ) , MEK1 (human) ( 62 , 360 ) , Merlin (human) ( 14 ) , Notch 1 (human) ( 381 ) , NRas (human) ( 239 ) , OLA1 (human) ( 17 ) , OSBPL8 (mouse) ( 111 ) , p16-INK4A (human) ( 33 ) , P2X7 (human) ( 24 ) , p53 (human) ( 381 ) , PARVB (human) ( 415 ) , PCGF2 (human) ( 347 ) , PGGT1B (mouse) ( 11 ) , PHLPP (human) ( 207 , 364 ) , PHLPP2 (human) ( 207 , 364 ) , PINK1 (human) ( 113 ) , PKCA (human) ( 240 ) , PKCE (human) ( 370 ) , PKCT (human) ( 49 ) , PPP1CA (human) ( 166 ) , PPP1R2 (human) ( 375 ) , PTEN (human) ( 465 ) , RAF1 (human) ( 62 ) , RPS23 (mouse) ( 242 ) , SGK1 (human) ( 28 ) , SHIP (human) ( 109 , 417 ) , SMAD7 (human) ( 413 ) , TACC3 (human) ( 25 ) , TGFB1 (human) ( 206 ) , TORC2 (mouse) ( 289 ) , TSC2 (human) ( 376 )
Putative in vivo kinases:
Akt1 (human) ( 7 , 432 ) , AurA (human) ( 292 ) , KHS1 (human) ( 378 ) , p90RSK (human) ( 398 , 468 ) , PIK3R1 (human) ( 237 ) , PKACA (human) ( 464 ) , PKCA (human) ( 451 ) , PKCB (human) ( 451 ) , PKCH (human) ( 451 ) , PKCZ (human) ( 22 ) , SGK3 (human) ( 449 )
Kinases, in vitro:
Akt1 (human) ( 417 , 453 , 455 , 460 , 467 ) , AurA (human) ( 292 ) , KHS1 (human) ( 378 ) , p70S6K (human) ( 467 , 468 ) , P70S6KB (human) ( 106 ) , p90RSK (human) ( 468 ) , PKACA (human) ( 464 ) , PKCA (human) ( 451 ) , PKCB iso2 (human) ( 451 ) , PKCD (human) ( 451 ) , PKCG (human) ( 451 ) , PKCH (human) ( 451 ) , RSK2 (human) ( 458 , 467 ) , SGK3 (human) ( 449 )
Putative upstream phosphatases:
laforin (human) ( 372 , 396 ) , PPP1CA (human) ( 393 ) , PPP2CA (human) ( 237 )
Phosphatases, in vitro:
laforin (human) ( 396 )
Treatments:
hyperoside ( 35 ) , 2-bromohexadecanoid_acid ( 374 ) , 2-deoxyglucose ( 251 , 443 ) , 3MCIC ( 20 ) , 4-HT ( 27 , 62 ) , 5-thio-glucose ( 443 ) , 6-OHDA ( 28 , 421 ) , A-443654 ( 315 ) , A740003 ( 24 ) , activin ( 62 ) , adenosine ( 34 ) , AG1478 ( 113 , 401 ) , Akt-I-1 ( 227 , 358 , 360 , 410 ) , Akt_inhibitor_VIII ( 292 ) , amino_acid_starvation ( 39 ) , amino_acids ( 397 ) , anthrax_toxin ( 358 ) , anti-Akt1 ( 406 ) , anti-CD3 ( 58 , 109 ) , anti-EPCR ( 310 ) , anti-FGF19 ( 346 ) , anti-IgM ( 9 ) , anti-ITGA4 ( 237 ) , anti-ITGA5 ( 237 ) , anti-PAR1 ( 310 ) , AP21967 ( 445 ) , APC ( 310 ) , apocynin ( 23 ) , ARC ( 355 ) , AZ1060120 ( 24 ) , AZD8055 ( 230 ) , BAPTA-AM ( 435 ) , BDNF ( 421 ) , bicalutamide ( 422 ) , BIM-23120 ( 380 ) , bisindolylmaleimide ( 370 ) , brefeldin_A ( 442 ) , BzATP ( 24 ) , caffeine ( 114 , 423 ) , calphostin_C ( 401 ) , calyculin_A ( 368 , 442 ) , cAMP_analog ( 444 , 464 ) , canertinib ( 351 ) , CDDO-Me ( 336 ) , cell_adhesion ( 237 ) , CHIR99021 ( 5 ) , ciclosporin ( 401 , 442 ) , colforsin ( 26 , 314 , 400 , 444 , 464 ) , collagen ( 434 ) , collagen XIX (NC1 domain) ( 19 ) , convulxin ( 434 ) , CTGF ( 117 ) , DAMGO ( 466 ) , depolarization ( 375 , 400 , 401 ) , derivative-2 ( 38 ) , EDTA ( 401 ) , eflornithine ( 315 ) , EGF ( 113 , 133 , 244 , 351 , 379 , 385 , 415 , 418 , 423 , 432 ) , englerin_A ( 49 ) , enzastaurin ( 316 , 342 , 350 ) , Epo ( 367 , 456 ) , erlotinib ( 407 ) , estradiol ( 225 , 374 ) , estren ( 374 ) , estrogen_deprivation ( 404 ) , exercise ( 391 ) , FGF19 ( 346 ) , FGF2 ( 62 ) , fibronectin ( 461 ) , fipronil ( 107 ) , FK506 ( 401 , 442 ) , fMLP ( 458 ) , gastrin ( 236 ) , gefitinib ( 235 , 431 ) , geldanamycin ( 431 ) , ginsenoside-Rg1 ( 371 ) , glucocorticoid ( 448 ) , glucose ( 416 , 443 ) , glucose_starvation ( 377 ) , H-7 ( 458 ) , H-89 ( 114 , 400 , 401 , 410 , 444 , 458 , 464 ) , H2O2 ( 386 , 463 ) , HA-1004 ( 458 ) , HA1077 ( 5 ) , HB-EGF ( 133 ) , heat_shock ( 454 ) , heregulin ( 62 ) , HGF ( 47 , 223 , 349 ) , homocysteine ( 34 ) , hypoxia ( 265 , 437 , 443 , 463 ) , IBMX ( 26 ) , idelalisib ( 9 ) , IGF-1 ( 62 , 362 , 400 , 407 , 410 , 418 , 430 , 432 , 442 , 464 ) , IL-1a ( 54 ) , IL-1b ( 195 ) , imatinib ( 235 ) , insulin ( 22 , 111 , 118 , 289 , 291 , 301 , 337 , 345 , 363 , 370 , 372 , 376 , 397 , 416 , 432 , 433 , 447 ) , ionizing_radiation ( 316 , 414 ) , ionomycin ( 99 ) , IP(6) ( 238 ) , IQA ( 402 ) , isoproterenol ( 464 ) , kenpaullone ( 107 , 342 ) , KHS101 ( 25 ) , KN-62 ( 400 , 401 ) , KN-92 ( 408 ) , KN-93 ( 408 ) , KP-372-1 ( 383 , 385 ) , KP-372-2 ( 385 ) , laminar flow ( 365 ) , leucine ( 39 ) , leucine_deprivation ( 39 ) , lithium ( 8 , 85 , 107 , 206 , 232 , 242 , 336 , 342 , 362 , 368 , 371 , 387 , 400 , 408 , 437 , 450 ) , low_Ca(2+) ( 401 ) , low_K(+) ( 400 ) , LPA ( 370 , 446 , 451 , 464 ) , LPS ( 11 , 106 , 412 , 462 ) , LTD4 ( 384 ) , LY2064827 ( 342 ) , LY294002 ( 18 , 62 , 85 , 227 , 243 , 244 , 310 , 313 , 315 , 358 , 362 , 371 , 373 , 374 , 379 , 384 , 401 , 402 , 410 , 413 , 422 , 430 , 432 , 434 , 437 , 443 , 444 , 446 , 450 , 452 , 454 , 458 , 462 , 464 ) , lysine ( 39 ) , lysine_deprivation ( 39 ) , mechanical stress ( 195 ) , metribolone ( 422 ) , MG132 ( 418 ) , mifepristone ( 371 ) , miRNA ( 31 ) , ML-9 ( 400 ) , NAC ( 421 ) , naloxone ( 466 ) , nifedipine ( 401 ) , okadaic_acid ( 34 , 237 , 401 , 421 , 442 ) , oscillatory_flow ( 365 ) , OSU-T315 ( 469 ) , ouabain ( 360 ) , PAO ( 368 ) , PD98059 ( 362 , 371 , 389 , 401 , 418 , 444 , 446 , 458 ) , PDGF ( 423 ) , phorbol_ester ( 99 , 368 , 369 ) , PI(3,4)P2 ( 314 ) , PLTP ( 243 ) , poly-L-lysine ( 461 ) , putrescine ( 315 ) , QLT0254 ( 411 ) , QLT0267 ( 395 ) , racepinefrine ( 118 ) , rapamycin ( 106 , 110 , 359 , 376 , 401 ) , resveratrol ( 23 , 233 ) , retinoic_acid ( 12 ) , RRD-251 ( 12 ) , S-valproate ( 349 ) , sardomozide ( 315 ) , SB203580 ( 413 , 446 ) , SB216763 ( 206 ) , SCF ( 456 ) , SCH_23390 ( 119 ) , Sem3A ( 450 ) , serum ( 373 , 379 , 423 , 444 , 448 , 452 , 457 , 465 ) , serum_starvation ( 60 ) , serum_withdrawal ( 387 , 452 , 454 ) , SH-6 ( 371 , 373 ) , siRNA ( 237 , 335 , 345 , 362 , 364 , 376 , 383 , 388 , 392 , 403 , 413 , 425 ) , SKF38393 ( 119 ) , SN-50 ( 400 ) , somatostatin ( 380 ) , spermidine ( 315 ) , spermine ( 315 ) , sphingosine_1-phosphate ( 388 , 446 ) , staurosporine ( 362 , 435 , 454 ) , Su11274 ( 235 ) , sunitinib ( 231 ) , tanespimycin ( 233 ) , TBB ( 402 ) , TGF-beta ( 85 , 413 ) , thapsigargin ( 421 , 427 , 435 , 442 ) , thrombin ( 434 ) , TNF ( 345 , 349 , 432 , 433 , 455 ) , TPO ( 367 ) , TRAIL ( 440 ) , tungstate ( 389 ) , tunicamycin ( 421 , 427 , 442 ) , U0126 ( 62 , 287 , 360 , 418 ) , U71322 ( 435 ) , UCN-01 ( 419 ) , UV ( 362 ) , W-5 ( 408 ) , W-7 ( 408 ) , Wnt3a ( 22 ) , Wnt5a ( 22 ) , wortmannin ( 225 , 233 , 235 , 236 , 311 , 401 , 410 , 412 , 418 , 430 , 434 , 450 , 455 , 458 , 462 , 464 ) , YM_022 ( 236 ) , Z-DEVD-fmk ( 336 ) , Z-IETD-fmk ( 336 ) , ZM198,615 ( 384 )

Downstream Regulation
Effects of modification on GSK3B:
activity, inhibited ( 396 , 399 , 400 , 457 ) , enzymatic activity, inhibited ( 62 , 301 , 336 , 387 , 389 , 393 , 398 , 432 , 441 , 448 , 450 , 456 , 459 , 464 , 468 ) , intracellular localization ( 432 ) , phosphorylation ( 432 ) , protein degradation ( 424 ) , protein processing ( 206 )
Effects of modification on biological processes:
apoptosis, altered ( 335 , 336 ) , apoptosis, inhibited ( 400 , 444 ) , cell adhesion, altered ( 444 ) , cell differentiation, induced ( 62 ) , cell growth, altered ( 432 ) , cell growth, induced ( 206 ) , cell motility, altered ( 236 ) , cytoskeletal reorganization ( 444 ) , transcription, altered ( 236 , 459 )

Disease / Diagnostics Relevance
Relevant diseases:
Alzheimer's disease ( 65 , 424 ) , bipolar disprder ( 368 ) , breast cancer ( 10 , 362 ) , lymphoma ( 234 ) , ovarian cancer ( 420 ) , pancreatic cancer ( 110 ) , melanoma skin cancer ( 239 ) , hypertrophic cardiomyopathy ( 206 ) , type 2 diabetes ( 424 ) , Parkinson's disease ( 21 ) , schizophrenia ( 428 )

References 

1

Islam R, et al. (2018) Insulin induces phosphorylation of pyruvate dehydrogenase through RhoA activation pathway in HepG2 cells. FASEB J, fj201800917R
30226812   Curated Info

2

Braekeveldt N, et al. (2018) Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma. Cancer Res
30154149   Curated Info

3

Liang J, et al. (2017) miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway. Oncotarget 8, 82991-83008
29137318   Curated Info

4

Dong J, et al. (2017) FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt. Oncotarget 8, 80405-80415
29113312   Curated Info

5

Dyberg C, et al. (2017) Rho-associated kinase is a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 114, E6603-E6612
28739902   Curated Info

6

Hur EH, et al. (2017) Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. Oncotarget 8, 41387-41400
28574827   Curated Info

7

Jin Y, et al. (2017) Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin. Clin Cancer Res 23, 2842-2855
27852702   Curated Info

8

Tobe BTD, et al. (2017) Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc Natl Acad Sci U S A 114, E4462-E4471
28500272   Curated Info

9

Yang Q, et al. (2017) Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res 23, 181-192
27342398   Curated Info

10

Ko HW, et al. (2016) GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget 7, 57131-57144
27494834   Curated Info

11

Akula MK, et al. (2016) Control of the innate immune response by the mevalonate pathway. Nat Immunol 17, 922-9
27270400   Curated Info

12

Wallace AS, Supnick HT, Bunaciu RP, Yen A (2016) RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Oncotarget 7, 46401-46418
27331409   Curated Info

13

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

14

Morrow KA, et al. (2016) Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget 7, 17991-8005
26908451   Curated Info

15

Liu T, et al. (2016) HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res 76, 572-81
26676747   Curated Info

16

Li S, et al. (2016) The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis. Dev Cell 36, 164-78
26812016   Curated Info

17

Xu D, et al. (2016) Obg-like ATPase 1 regulates global protein serine/threonine phosphorylation in cancer cells by suppressing the GSK3β-inhibitor 2-PP1 positive feedback loop. Oncotarget 7, 3427-39
26655089   Curated Info

18

Sakurikar N, Thompson R, Montano R, Eastman A (2016) A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase. Oncotarget 7, 1380-94
26595527   Curated Info

19

Oudart JB, et al. (2016) The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction. Oncotarget 7, 1516-28
26621838   Curated Info

20

Cao L, Zhang L, Zhao X, Zhang Y (2016) A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLoS One 11, e0161025
27525972   Curated Info

21

Xing H, et al. (2016) Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain 9, 84
27609071   Curated Info

22

Tejeda-Muñoz N, et al. (2015) Glycogen Synthase Kinase 3β Is Positively Regulated by Protein Kinase Cζ-Mediated Phosphorylation Induced by Wnt Agonists. Mol Cell Biol 36, 731-41
26711256   Curated Info

23

Kato A, et al. (2015) Chemopreventive effect of resveratrol and apocynin on pancreatic carcinogenesis via modulation of nuclear phosphorylated GSK3β and ERK1/2. Oncotarget 6, 42963-75
26556864   Curated Info

24

Amoroso F, et al. (2015) The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene 34, 5240-51
25619831   Curated Info

25

Zhou DS, et al. (2015) TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget 6, 24163-77
26219398   Curated Info

26

Whiting JL, et al. (2015) Protein Kinase A Opposes the Phosphorylation-dependent Recruitment of Glycogen Synthase Kinase 3β to A-kinase Anchoring Protein 220. J Biol Chem 290, 19445-57
26088133   Curated Info

27

Wiese KE, et al. (2015) Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells. EMBO J 34, 1554-71
25896507   Curated Info

28

Iqbal S, Howard S, LoGrasso PV (2015) Serum- and Glucocorticoid-Inducible Kinase 1 Confers Protection in Cell-Based and in In Vivo Neurotoxin Models via the c-Jun N-Terminal Kinase Signaling Pathway. Mol Cell Biol 35, 1992-2006
25825522   Curated Info

29

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

30

Zhang B, et al. (2015) GSK3β-Dzip1-Rab8 Cascade Regulates Ciliogenesis after Mitosis. PLoS Biol 13, e1002129
25860027   Curated Info

31

Zhang H, et al. (2015) miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget 6, 6092-104
25714029   Curated Info

32

Gao F, Al-Azayzih A, Somanath PR (2015) Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis. Oncotarget 6, 5947-62
25714023   Curated Info

33

Damsky W, et al. (2015) mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27, 41-56
25584893   Curated Info

34

Dudiki T, et al. (2015) Changes in Carboxy Methylation and Tyrosine Phosphorylation of Protein Phosphatase PP2A Are Associated with Epididymal Sperm Maturation and Motility. PLoS One 10, e0141961
26569399   Curated Info

35

Xing HY, et al. (2015) The Cytoprotective Effect of Hyperoside against Oxidative Stress Is Mediated by the Nrf2-ARE Signaling Pathway through GSK-3β Inactivation. PLoS One 10, e0145183
26674355   Curated Info

36

Gjyshi O, et al. (2014) Kaposi's sarcoma-associated herpesvirus induces Nrf2 during de novo infection of endothelial cells to create a microenvironment conducive to infection. PLoS Pathog 10, e1004460
25340789   Curated Info

37

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

38

Watanabe T, et al. (2014) Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma. Biochem Biophys Res Commun 451, 93-100
25063029   Curated Info

39

Saha A, et al. (2014) Akt phosphorylation and regulation of transketolase is a nodal point for amino Acid control of purine synthesis. Mol Cell 55, 264-76
24981175   Curated Info

40

Kao SH, et al. (2014) GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 33, 3172-82
23851495   Curated Info

41

Nicot AS, et al. (2014) Phosphorylation of NBR1 by GSK3 modulates protein aggregation. Autophagy 10, 1036-53
24879152   Curated Info

42

Mirzaa GM, et al. (2014) De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome. Nat Genet 46, 510-5
24705253   Curated Info

43

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

44

Nardi F, et al. (2014) Enhanced Insulin Sensitivity Associated with Provision of Mono and Polyunsaturated Fatty Acids in Skeletal Muscle Cells Involves Counter Modulation of PP2A. PLoS One 9, e92255
24632852   Curated Info

45

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

46

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

47

Radtke S, et al. (2013) ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci 126, 2381-91
23549785   Curated Info

48

Luo Y, et al. (2013) PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B. Biochim Biophys Acta 1833, 1235-43
23428800   Curated Info

49

Sourbier C, et al. (2013) Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell 23, 228-37
23352416   Curated Info

50

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

51

Chen S, et al. (2013) Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Sci Signal 6, ra40
23716717   Curated Info

52

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

53

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

54

Gulen MF, et al. (2012) Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37, 800-12
23142783   Curated Info

55

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

56

Manser C, et al. (2012) Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene 31, 2773-82
21996745   Curated Info

57

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

58

Ruperez P, Gago-Martinez A, Burlingame AL, Oses-Prieto JA (2012) Quantitative phosphoproteomic analysis reveals a role for serine and threonine kinases in the cytoskeletal reorganization in early T cell receptor activation in human primary T cells. Mol Cell Proteomics 11, 171-86
22499768   Curated Info

59

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

60

Lin SY, et al. (2012) GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science 336, 477-81
22539723   Curated Info

61

Mulhern D (2012) CST Curation Set: 13830; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

62

Singh AM, et al. (2012) Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10, 312-26
22385658   Curated Info

63

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

64

Mulhern D (2012) CST Curation Set: 13108; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

65

Israel MA, et al. (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-20
22278060   Curated Info

66

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

67

Rho SB, et al. (2012) Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal 24, 131-9
21893193   Curated Info

68

Mulhern D (2011) CST Curation Set: 12833; Year: 2011; Biosample/Treatment: cell line, HEK 293/ku-0063794; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

69

Mulhern D (2011) CST Curation Set: 12838; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

70

Mulhern D (2011) CST Curation Set: 12839; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

71

Mulhern D (2011) CST Curation Set: 12840; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

72

Mulhern D (2011) CST Curation Set: 12841; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

73

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

74

Rikova K (2011) CST Curation Set: 13130; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

75

Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

76

Rikova K (2011) CST Curation Set: 13132; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

77

Mulhern D (2011) CST Curation Set: 12759; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

78

Mulhern D (2011) CST Curation Set: 12760; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

79

Mulhern D (2011) CST Curation Set: 12752; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

80

Mulhern D (2011) CST Curation Set: 12753; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

81

Mulhern D (2011) CST Curation Set: 12754; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

82

Mulhern D (2011) CST Curation Set: 12755; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

83

Rapley J, Oshiro N, Ortiz-Vega S, Avruch J (2011) The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling. J Biol Chem 286, 38043-53
21914810   Curated Info

84

Guo JP, Coppola D, Cheng JQ (2011) IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 286, 37389-98
21908616   Curated Info

85

Wu J, et al. (2011) HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug. Oncogene 30, 4410-27
21532623   Curated Info

86

Mulhern D (2011) CST Curation Set: 12685; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

87

Mulhern D (2011) CST Curation Set: 12677; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

88

Mulhern D (2011) CST Curation Set: 12678; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

89

Mulhern D (2011) CST Curation Set: 12679; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

90

Mulhern D (2011) CST Curation Set: 12680; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

91

Mulhern D (2011) CST Curation Set: 12681; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

92

Mulhern D (2011) CST Curation Set: 12683; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

93

Chen S, et al. (2011) Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer Res 71, 6270-81
21868755   Curated Info

94

Mounir Z, et al. (2011) Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway. Sci Signal 4, ra62
21954288   Curated Info

95

Guo A (2011) CST Curation Set: 12069; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

96

Guo A (2011) CST Curation Set: 12073; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

97

Guo A (2011) CST Curation Set: 12074; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

98

Yao S, et al. (2011) B7-h2 is a costimulatory ligand for CD28 in human. Immunity 34, 729-40
21530327   Curated Info

99

Neumann M, et al. (2011) Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation. Oncogene 30, 2485-92
21217772   Curated Info

100

Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

101

Moritz A (2011) CST Curation Set: 11933; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

102

Moritz A (2011) CST Curation Set: 11937; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

103

Moritz A (2011) CST Curation Set: 11938; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

104

Moritz A (2011) CST Curation Set: 11940; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

105

Moritz A (2011) CST Curation Set: 11943; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

106

Wang H, et al. (2011) Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol 186, 5217-26
21422248   Curated Info

107

Lee JE, et al. (2011) Akt/GSK3β signaling is involved in fipronil-induced apoptotic cell death of human neuroblastoma SH-SY5Y cells. Toxicol Lett 202, 133-41
21296133   Curated Info

108

Xie X, et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 108, 6474-9
21464307   Curated Info

109

Harris SJ, et al. (2011) Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility. J Immunol 186, 4936-45
21402888   Curated Info

110

Kennedy AL, et al. (2011) Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42, 36-49
21474066   Curated Info

111

Jordan SD, et al. (2011) Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 13, 434-46
21441927   Curated Info

112

Thayyullathil F, et al. (2011) Protein phosphatase 1-dependent dephosphorylation of Akt is the prime signaling event in sphingosine-induced apoptosis in Jurkat cells. J Cell Biochem 112, 1138-53
21308747   Curated Info

113

Murata H, et al. (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 286, 7182-9
21177249   Curated Info

114

Ku BM, et al. (2011) Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells. Mol Cells 31, 275-9
21229324   Curated Info

115

Guo A (2011) CST Curation Set: 11299; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

116

Guo A (2011) CST Curation Set: 11302; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

117

Rooney B, et al. (2011) CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett 585, 531-8
21237163   Curated Info

118

Jensen J, et al. (2011) Effects of adrenaline on whole-body glucose metabolism and insulin-mediated regulation of glycogen synthase and PKB phosphorylation in human skeletal muscle. Metabolism 60, 215-26
20153492   Curated Info

119

Lebel M, Cyr M (2011) Molecular and cellular events of dopamine D1 receptor-mediated tau phosphorylation in SK-N-MC cells. Synapse 65, 69-76
20506302   Curated Info

120

Rikova K (2011) CST Curation Set: 11015; Year: 2011; Biosample/Treatment: cell line, NCI-H2073/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

121

Rikova K (2011) CST Curation Set: 11007; Year: 2011; Biosample/Treatment: cell line, LOU-NH91/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

122

Rikova K (2011) CST Curation Set: 11013; Year: 2011; Biosample/Treatment: cell line, NCI-H226/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

123

Rikova K (2011) CST Curation Set: 11018; Year: 2011; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

124

Rikova K (2011) CST Curation Set: 11006; Year: 2011; Biosample/Treatment: cell line, NCI-H1975/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

125

Rikova K (2011) CST Curation Set: 11016; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

126

Rikova K (2011) CST Curation Set: 11009; Year: 2011; Biosample/Treatment: cell line, DV-90/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

127

Rikova K (2011) CST Curation Set: 11004; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

128

Rikova K (2011) CST Curation Set: 11005; Year: 2011; Biosample/Treatment: cell line, Calu-3/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

129

Rikova K (2011) CST Curation Set: 11019; Year: 2011; Biosample/Treatment: cell line, NCI-H2170/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

130

Chen CH, et al. (2011) ER Stress Inhibits mTORC2 and Akt Signaling Through GSK-3{beta}-Mediated Phosphorylation of Rictor. Sci Signal 4, ra10
21343617   Curated Info

131

Yung HW, Charnock-Jones DS, Burton GJ (2011) Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 6, e17894
21445305   Curated Info

132

Sundaresan NR, et al. (2011) The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4, ra46
21775285   Curated Info

133

Wright JK, et al. (2010) HER1 Signaling Mediates Extravillous Trophoblast Differentiation in Humans. Biol Reprod 83, 1036-45
20739666   Curated Info

134

Lei CQ, et al. (2010) Glycogen synthase kinase 3β regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity 33, 878-89
21145761   Curated Info

135

Karyo R, et al. (2010) Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci 45, 449-55
20708687   Curated Info

136

Possemato A (2010) CST Curation Set: 10867; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

137

Possemato A (2010) CST Curation Set: 10869; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

138

Possemato A (2010) CST Curation Set: 10868; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

139

Possemato A (2010) CST Curation Set: 10959; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

140

Possemato A (2010) CST Curation Set: 10783; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

141

Possemato A (2010) CST Curation Set: 10790; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

142

Possemato A (2010) CST Curation Set: 10781; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

143

Possemato A (2010) CST Curation Set: 10789; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

144

Possemato A (2010) CST Curation Set: 10782; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

145

Possemato A (2010) CST Curation Set: 10787; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

146

Possemato A (2010) CST Curation Set: 10788; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

147

Possemato A (2010) CST Curation Set: 10785; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

148

Possemato A (2010) CST Curation Set: 10793; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

149

Possemato A (2010) CST Curation Set: 10786; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

150

Possemato A (2010) CST Curation Set: 10792; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

151

Possemato A (2010) CST Curation Set: 10780; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

152

Possemato A (2010) CST Curation Set: 10784; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

153

Possemato A (2010) CST Curation Set: 10838; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

154

Possemato A (2010) CST Curation Set: 10777; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

155

Possemato A (2010) CST Curation Set: 10775; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

156

Possemato A (2010) CST Curation Set: 10774; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

157

Possemato A (2010) CST Curation Set: 10778; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

158

Possemato A (2010) CST Curation Set: 10779; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

159

Possemato A (2010) CST Curation Set: 10714; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

160

Possemato A (2010) CST Curation Set: 10734; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

161

Possemato A (2010) CST Curation Set: 10726; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

162

Possemato A (2010) CST Curation Set: 10730; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

163

Possemato A (2010) CST Curation Set: 10733; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

164

Possemato A (2010) CST Curation Set: 10728; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

165

Possemato A (2010) CST Curation Set: 10731; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

166

Xiao L, et al. (2010) Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ 17, 1448-62
20186153   Curated Info

167

Possemato A (2010) CST Curation Set: 10531; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

168

Possemato A (2010) CST Curation Set: 10157; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

169

Possemato A (2010) CST Curation Set: 10146; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

170

Possemato A (2010) CST Curation Set: 10150; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

171

Possemato A (2010) CST Curation Set: 10160; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

172

Possemato A (2010) CST Curation Set: 10161; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

173

Possemato A (2010) CST Curation Set: 10158; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

174

Possemato A (2010) CST Curation Set: 10142; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

175

Possemato A (2010) CST Curation Set: 10162; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

176

Possemato A (2010) CST Curation Set: 10143; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

177

Possemato A (2010) CST Curation Set: 10156; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

178

Possemato A (2010) CST Curation Set: 10155; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

179

Possemato A (2010) CST Curation Set: 10154; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

180

Possemato A (2010) CST Curation Set: 10159; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

181

Possemato A (2010) CST Curation Set: 10147; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

182

Possemato A (2010) CST Curation Set: 10163; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

183

Possemato A (2010) CST Curation Set: 10151; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

184

Possemato A (2010) CST Curation Set: 10122; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

185

Possemato A (2010) CST Curation Set: 10121; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

186

Possemato A (2010) CST Curation Set: 10118; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

187

Possemato A (2010) CST Curation Set: 10123; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

188

Possemato A (2010) CST Curation Set: 10125; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

189

Possemato A (2010) CST Curation Set: 10120; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

190

Beausoleil S (2010) CST Curation Set: 10285; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

191

Beausoleil S (2010) CST Curation Set: 10278; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

192

Beausoleil S (2010) CST Curation Set: 10284; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

193

Beausoleil S (2010) CST Curation Set: 10280; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

194

Beausoleil S (2010) CST Curation Set: 10279; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

195

Liu J, Agarwal S (2010) Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J Immunol 185, 1215-21
20548028   Curated Info

196

Possemato A (2010) CST Curation Set: 10165; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

197

Possemato A (2010) CST Curation Set: 10166; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

198

Possemato A (2010) CST Curation Set: 10127; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

199

Possemato A (2010) CST Curation Set: 10126; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

200

Guo A (2010) CST Curation Set: 9944; Year: 2010; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

201

Guo A (2010) CST Curation Set: 9943; Year: 2010; Biosample/Treatment: cell line, LAN-6/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

202

Guo A (2010) CST Curation Set: 9942; Year: 2010; Biosample/Treatment: cell line, SMS-KCN-A/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

203

Guo A (2010) CST Curation Set: 9946; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/NGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

204

Guo A (2010) CST Curation Set: 9945; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

205

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

206

Deng H, et al. (2010) Pulmonary artery smooth muscle hypertrophy: roles of glycogen synthase kinase-3beta and p70 ribosomal S6 kinase. Am J Physiol Lung Cell Mol Physiol 298, L793-803
20190034   Curated Info

207

Qiao M, et al. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38, 512-23
20513427   Curated Info

208

Possemato A (2010) CST Curation Set: 9732; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

209

Possemato A (2010) CST Curation Set: 9629; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

210

Possemato A (2010) CST Curation Set: 9624; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

211

Possemato A (2010) CST Curation Set: 9627; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

212

Possemato A (2010) CST Curation Set: 9628; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

213

Possemato A (2010) CST Curation Set: 9630; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

214

Possemato A (2010) CST Curation Set: 9631; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

215

Possemato A (2010) CST Curation Set: 9620; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

216

Possemato A (2010) CST Curation Set: 9623; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

217

Possemato A (2010) CST Curation Set: 9621; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

218

Possemato A (2010) CST Curation Set: 9622; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

219

Possemato A (2010) CST Curation Set: 9618; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

220

Possemato A (2010) CST Curation Set: 9625; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

221

Possemato A (2010) CST Curation Set: 9626; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

222

Possemato A (2010) CST Curation Set: 9619; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

223

Goodwin CR, et al. (2010) Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. Cancer Res 70, 2932-41
20233866   Curated Info

224

Mallon R, et al. (2010) Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther 9, 976-84
20371716   Curated Info

225

Ye Y, et al. (2010) ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 29, 1451-62
20101232   Curated Info

226

Possemato A (2010) CST Curation Set: 9254; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

227

Singh A, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21, 1140-52
20110348   Curated Info

228

Possemato A (2010) CST Curation Set: 9068; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

229

Possemato A (2010) CST Curation Set: 9071; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

230

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

231

Yang F, et al. (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8, 35-45
20053726   Curated Info

232

Terracciano C, Nogalska A, Engel WK, Askanas V (2010) In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 112, 389-96
19878439   Curated Info

233

Banerjee Mustafi S, Chakraborty PK, Raha S (2010) Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS One 5, e8719
20090934   Curated Info

234

Chung R, et al. (2010) Biological and clinical significance of GSK-3beta in mantle cell lymphoma--an immunohistochemical study. Int J Clin Exp Pathol 3, 244-53
20224723   Curated Info

235

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

236

Mishra P, Senthivinayagam S, Rana A, Rana B (2010) Glycogen Synthase Kinase-3beta regulates Snail and beta-catenin during gastrin-induced migration of gastric cancer cells. J Mol Signal 5, 9
20637111   Curated Info

237

De Toni-Costes F, et al. (2010) A New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells. PLoS One 5, e9807
20352103   Curated Info

238

Gu M, et al. (2009) Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res 69, 9465-72
19920184   Curated Info

239

Davies MA, et al. (2009) Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15, 7538-7546
19996208   Curated Info

240

Haughian JM, Reno EM, Thorne AM, Bradford AP (2009) Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer 125, 2556-64
19672862   Curated Info

241

Li X, Liu J, Gao T (2009) beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol Cell Biol 29, 6192-205
19797085   Curated Info

242

Zhang YW, et al. (2009) A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation. Neuron 64, 328-40
19914182   Curated Info

243

Dong W, Albers JJ, Vuletic S (2009) Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. J Neurosci Res 87, 3176-85
19472218   Curated Info

244

Wang Z, et al. (2009) Dependence of EGF-induced increases in corneal epithelial proliferation and migration on GSK-3 inactivation. Invest Ophthalmol Vis Sci 50, 4828-35
19443725   Curated Info

245

Zhou J (2009) CST Curation Set: 7640; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

246

Zhou J (2009) CST Curation Set: 7643; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

247

Zhou J (2009) CST Curation Set: 7644; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

248

Zhou J (2009) CST Curation Set: 7641; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

249

Zhou J (2009) CST Curation Set: 7642; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

250

Zhou J (2009) CST Curation Set: 7639; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

251

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

252

Possemato A (2009) CST Curation Set: 7415; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

253

Possemato A (2009) CST Curation Set: 7416; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

254

Possemato A (2009) CST Curation Set: 7407; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

255

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

256

Possemato A (2009) CST Curation Set: 7267; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

257

Possemato A (2009) CST Curation Set: 7268; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

258

Possemato A (2009) CST Curation Set: 7263; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

259

Possemato A (2009) CST Curation Set: 7261; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

260

Possemato A (2009) CST Curation Set: 7259; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

261

Possemato A (2009) CST Curation Set: 7262; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

262

Possemato A (2009) CST Curation Set: 7264; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

263

Ren H (2009) CST Curation Set: 7180; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

264

Zhou J (2009) CST Curation Set: 7214; Year: 2009; Biosample/Treatment: cell line, LNCaP/untreated; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

265

Chiang MH, et al. (2009) Mechanism of Hypoxia-induced GCM1 Degradation: IMPLICATIONS FOR THE PATHOGENESIS OF PREECLAMPSIA. J Biol Chem 284, 17411-9
19416964   Curated Info

266

Possemato A (2009) CST Curation Set: 6913; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

267

Possemato A (2009) CST Curation Set: 6914; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

268

Possemato A (2009) CST Curation Set: 6915; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

269

Possemato A (2009) CST Curation Set: 6908; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

270

Possemato A (2009) CST Curation Set: 6909; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

271

Possemato A (2009) CST Curation Set: 6910; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

272

Possemato A (2009) CST Curation Set: 6911; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

273

Possemato A (2009) CST Curation Set: 6912; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

274

Possemato A (2009) CST Curation Set: 6904; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

275

Li Y (2009) CST Curation Set: 6879; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

276

Possemato A (2009) CST Curation Set: 6905; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

277

Possemato A (2009) CST Curation Set: 6906; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

278

Possemato A (2009) CST Curation Set: 6907; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

279

Possemato A (2009) CST Curation Set: 6902; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

280

Possemato A (2009) CST Curation Set: 6903; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

281

Possemato A (2009) CST Curation Set: 6901; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

282

Possemato A (2009) CST Curation Set: 6900; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

283

Possemato A (2009) CST Curation Set: 6898; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

284

Possemato A (2009) CST Curation Set: 6899; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

285

Possemato A (2009) CST Curation Set: 6896; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

286

Possemato A (2009) CST Curation Set: 6897; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

287

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

288

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

289

Ryu D, et al. (2009) TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab 9, 240-51
19254569   Curated Info

290

Farnsworth C (2009) CST Curation Set: 6186; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

291

Zong H, et al. (2009) Insulin resistance in striated muscle-specific integrin receptor beta1-deficient mice. J Biol Chem 284, 4679-88
19064993   Curated Info

292

Dar AA, Belkhiri A, El-Rifai W (2009) The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene 28, 866-75
19060929   Curated Info

293

Zhou J (2009) CST Curation Set: 6052; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

294

Zhou J (2009) CST Curation Set: 6054; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

295

Zhou J (2009) CST Curation Set: 6053; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

296

Zhou J (2009) CST Curation Set: 6049; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

297

Zhou J (2009) CST Curation Set: 6050; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

298

Zhou J (2009) CST Curation Set: 6048; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

299

Zhou J (2009) CST Curation Set: 6051; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

300

Zhou J (2009) CST Curation Set: 6047; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

301

Nemoto T, Yanagita T, Kanai T, Wada A (2009) Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: the role of GSK-3beta in the maintenance of steady-state levels of insulin receptor signaling molecules and Na(v)1.7 sodium channel in adrenal chromaffin cells. J Pharmacol Sci 109, 157-61
19179806   Curated Info

302

Moritz A (2009) CST Curation Set: 5890; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

303

Moritz A (2009) CST Curation Set: 5891; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

304

Moritz A (2009) CST Curation Set: 5893; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

305

Moritz A (2009) CST Curation Set: 5894; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

306

Moritz A (2009) CST Curation Set: 5888; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

307

Moritz A (2009) CST Curation Set: 5884; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

308

Moritz A (2009) CST Curation Set: 5885; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

309

Moritz A (2009) CST Curation Set: 5887; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

310

Yang XV, et al. (2009) Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A 106, 274-9
19116273   Curated Info

311

Wu Y, Evers BM, Zhou BP (2009) Small C-terminal Domain Phosphatase Enhances Snail Activity through Dephosphorylation. J Biol Chem 284, 640-8
19004823   Curated Info

312

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

313

Chua BT, et al. (2009) Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Mol Cancer 8, 131
20042122   Curated Info

314

Monje PV, Athauda G, Wood PM (2008) Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem 283, 34087-100
18799465   Curated Info

315

Koomoa DL, et al. (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68, 9825-31
19047162   Curated Info

316

Spalding AC, et al. (2008) Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells. Transl Oncol 1, 195-201
19043530   Curated Info

317

Moritz A (2008) CST Curation Set: 5660; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

318

Moritz A (2008) CST Curation Set: 5659; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

319

Moritz A (2008) CST Curation Set: 5650; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

320

Moritz A (2008) CST Curation Set: 5651; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

321

Moritz A (2008) CST Curation Set: 5653; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

322

Moritz A (2008) CST Curation Set: 5654; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

323

Moritz A (2008) CST Curation Set: 5656; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

324

Moritz A (2008) CST Curation Set: 5657; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

325

Ouchi N, et al. (2008) Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 283, 32802-11
18718903   Curated Info

326

Moritz A (2008) CST Curation Set: 5443; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

327

Moritz A (2008) CST Curation Set: 5444; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

328

Moritz A (2008) CST Curation Set: 5446; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

329

Moritz A (2008) CST Curation Set: 5447; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

330

Moritz A (2008) CST Curation Set: 5376; Year: 2008; Biosample/Treatment: cell line, MKN-45/U 0126; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

331

Moritz A (2008) CST Curation Set: 5377; Year: 2008; Biosample/Treatment: cell line, MKN-45/U 0126; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

332

Moritz A (2008) CST Curation Set: 5379; Year: 2008; Biosample/Treatment: cell line, MKN-45/wortmannin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

333

Moritz A (2008) CST Curation Set: 5382; Year: 2008; Biosample/Treatment: cell line, MKN-45/rapamycin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

334

Moritz A (2008) CST Curation Set: 5383; Year: 2008; Biosample/Treatment: cell line, MKN-45/rapamycin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

335

Zhong D, et al. (2008) LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res 68, 7270-7
18794113   Curated Info

336

Venè R, et al. (2008) Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res 68, 6987-96
18757413   Curated Info

337

Greenhaff PL, et al. (2008) Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 295, E595-604
18577697   Curated Info

338

Moritz A (2008) CST Curation Set: 5009; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

339

Moritz A (2008) CST Curation Set: 5010; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

340

Moritz A (2008) CST Curation Set: 5013; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

341

Moritz A (2008) CST Curation Set: 5014; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

342

Kotliarova S, et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68, 6643-51
18701488   Curated Info

343

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

344

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

345

Austin RL, et al. (2008) siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 57, 2066-73
18443205   Curated Info

346

Pai R, et al. (2008) Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 68, 5086-95
18593907   Curated Info

347

Lee JY, et al. (2008) Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res 68, 4201-9
18519679   Curated Info

348

Thornton TM, et al. (2008) Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 320, 667-70
18451303   Curated Info

349

Gong R, et al. (2008) Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem 283, 7401-10
18201972   Curated Info

350

Lee KW, et al. (2008) Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 68, 1916-26
18339873   Curated Info

351

Wen Y, et al. (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28, 2624-32
18322105   Curated Info

352

Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

353

Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

354

Singh K, et al. (2008) Synoviocyte stimulation by the LFA-1-intercellular adhesion molecule-2-Ezrin-Akt pathway in rheumatoid arthritis. J Immunol 180, 1971-8
18209096   Curated Info

355

Radhakrishnan SK, et al. (2008) Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. Oncogene 27, 694-9
17724478   Curated Info

356

Belkhiri A, et al. (2008) t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 68, 395-403
18199533   Curated Info

357

Kang T, et al. (2008) GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13, 36-47
18167338   Curated Info

358

Ha SD, Ng D, Pelech SL, Kim SO (2007) Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and MEK cleavage in macrophages. J Biol Chem 282, 36230-9
17951252   Curated Info

359

Martin KA, et al. (2007) Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. J Biol Chem 282, 36112-20
17908691   Curated Info

360

Khundmiri SJ, et al. (2007) Ouabain stimulates protein kinase B (Akt) phosphorylation in opossum kidney proximal tubule cells through an ERK-dependent pathway. Am J Physiol Cell Physiol 293, C1171-80
17634416   Curated Info

361

Palazzolo I, et al. (2007) Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 16, 1593-603
17470458   Curated Info

362

Ding Q, et al. (2007) Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 67, 4564-71
17495324   Curated Info

363

Litherland GJ, Morris NJ, Walker M, Yeaman SJ (2007) Role of glycogen content in insulin resistance in human muscle cells. J Cell Physiol 211, 344-52
17167773   Curated Info

364

Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-31
17386267   Curated Info

365

Guo D, Chien S, Shyy JY (2007) Regulation of endothelial cell cycle by laminar versus oscillatory flow: distinct modes of interactions of AMP-activated protein kinase and Akt pathways. Circ Res 100, 564-71
17272808   Curated Info

366

Wissing J, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6, 537-47
17192257   Curated Info

367

Rocher G, Letourneux C, Lenormand P, Porteu F (2007) Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 282, 5468-77
17200115   Curated Info

368

Li X, et al. (2007) Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 61, 216-22
16806104   Curated Info

369

Barragán M, et al. (2006) Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol 80, 1473-9
16940331   Curated Info

370

Eng CH, Huckaba TM, Gundersen GG (2006) The formin mDia regulates GSK3beta through novel PKCs to promote microtubule stabilization but not MTOC reorientation in migrating fibroblasts. Mol Biol Cell 17, 5004-16
16987962   Curated Info

371

Leung KW, Pon YL, Wong RN, Wong AS (2006) Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cells. J Biol Chem 281, 36280-8
17008323   Curated Info

372

Liu Y, et al. (2006) Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling. J Biol Chem 281, 34768-74
16971387   Curated Info

373

Van Meter TE, Broaddus WC, Cash D, Fillmore H (2006) Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. Cancer 107, 2446-54
17041888   Curated Info

374

Acconcia F, et al. (2006) An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. Cancer Res 66, 11030-8
17108142   Curated Info

375

King TD, Gandy JC, Bijur GN (2006) The protein phosphatase-1/inhibitor-2 complex differentially regulates GSK3 dephosphorylation and increases sarcoplasmic/endoplasmic reticulum calcium ATPase 2 levels. Exp Cell Res 312, 3693-700
16987514   Curated Info

376

Zhang HH, et al. (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 24, 185-97
17052453   Curated Info

377

Inoki K, et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126, 955-68
16959574   Curated Info

378

Shi CS, et al. (2006) The mitogen-activated protein kinase kinase kinase kinase GCKR positively regulates canonical and noncanonical Wnt signaling in B lymphocytes. Mol Cell Biol 26, 6511-21
16914735   Curated Info

379

Chao OS, Clément MV (2006) Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells. Oncogene 25, 4458-69
16767165   Curated Info

380

Tagliati F, et al. (2006) Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 147, 3530-8
16601140   Curated Info

381

Mungamuri SK, Yang X, Thor AD, Somasundaram K (2006) Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66, 4715-24
16651424   Curated Info

382

Taurin S, et al. (2006) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281, 9971-6
16476742   Curated Info

383

Zeng Z, et al. (2006) Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66, 3737-46
16585200   Curated Info

384

Mezhybovska M, Wikström K, Ohd JF, Sjölander A (2006) The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J Biol Chem 281, 6776-84
16407243   Curated Info

385

Koul D, et al. (2006) Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 5, 637-44
16546978   Curated Info

386

Benassi B, et al. (2006) c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 21, 509-19
16483932   Curated Info

387

Yin L, Wang J, Klein PS, Lazar MA (2006) Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311, 1002-5
16484495   Curated Info

388

Gonzalez E, Kou R, Michel T (2006) Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells. J Biol Chem 281, 3210-6
16339142   Curated Info

389

Gómez-Ramos A, et al. (2006) Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation. J Neurosci Res 83, 264-73
16397900   Curated Info

390

Wingate AD, Campbell DG, Peggie M, Arthur JS (2006) Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem J 393, 715-24
16223362   Curated Info

391

Wilson C, Hargreaves M, Howlett KF (2006) Exercise does not alter subcellular localization, but increases phosphorylation of insulin-signaling proteins in human skeletal muscle. Am J Physiol Endocrinol Metab 290, E341-6
16188907   Curated Info

392

Ooms LM, et al. (2006) The inositol polyphosphate 5-phosphatase, PIPP, Is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation. Mol Biol Cell 17, 607-22
16280363   Curated Info

393

Szatmari E, et al. (2005) A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J Biol Chem 280, 37526-35
16155008   Curated Info

394

Mori J, et al. (2005) Differentiation-inducing factor-1 induces cyclin D1 degradation through the phosphorylation of Thr286 in squamous cell carcinoma. Exp Cell Res 310, 426-33
16153639   Curated Info

395

Koul D, et al. (2005) Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4, 1681-8
16275989   Curated Info

396

Lohi H, et al. (2005) Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum Mol Genet 14, 2727-36
16115820   Curated Info

397

Tremblay F, et al. (2005) Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 54, 2674-84
16123357   Curated Info

398

Ding Q, et al. (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19, 159-70
16039586   Curated Info

399

Xu XM, Zhou YQ, Wang MH (2005) Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem 280, 25087-94
15878878   Curated Info

400

Chin PC, Majdzadeh N, D'Mello SR (2005) Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 137, 193-201
15950778   Curated Info

401

Lee YI, et al. (2005) Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3beta, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells. J Biol Chem 280, 22044-52
15799972   Curated Info

402

Di Maira G, et al. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12, 668-77
15818404   Curated Info

403

Duxbury MS, et al. (2005) RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res 11, 3433-8
15867245   Curated Info

404

Sabnis GJ, Jelovac D, Long B, Brodie A (2005) The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65, 3903-10
15867390   Curated Info

405

Gao T, Furnari F, Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18, 13-24
15808505   Curated Info

406

Shin I, et al. (2005) Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res 65, 2815-24
15805282   Curated Info

407

Thelemann A, et al. (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 4, 356-76
15657067   Curated Info

408

Kremenevskaja N, et al. (2005) Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24, 2144-54
15735754   Curated Info

409

Corradetti MN, Inoki K, Guan KL (2005) The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 280, 9769-72
15632201   Curated Info

410

Subramaniam S, et al. (2005) Insulin-like growth factor 1 inhibits extracellular signal-regulated kinase to promote neuronal survival via the phosphatidylinositol 3-kinase/protein kinase A/c-Raf pathway. J Neurosci 25, 2838-52
15772344   Curated Info

411

Yau CY, Wheeler JJ, Sutton KL, Hedley DW (2005) Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 65, 1497-504
15735038   Curated Info

412

Basak C, et al. (2005) NF-kappaB- and C/EBPbeta-driven interleukin-1beta gene expression and PAK1-mediated caspase-1 activation play essential roles in interleukin-1beta release from Helicobacter pylori lipopolysaccharide-stimulated macrophages. J Biol Chem 280, 4279-88
15561713   Curated Info

413

Edlund S, et al. (2005) Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 25, 1475-88
15684397   Curated Info

414

Carón RW, et al. (2005) Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 4, 257-70
15713897   Curated Info

415

Mongroo PS, et al. (2004) Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer. Oncogene 23, 8959-70
15467740   Curated Info

416

Zang M, et al. (2004) AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279, 47898-905
15371448   Curated Info

417

Horn S, et al. (2004) Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 18, 1839-49
15457186   Curated Info

418

Zhou BP, et al. (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6, 931-40
15448698   Curated Info

419

Shankar SL, et al. (2004) UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines. J Neurochem 90, 702-11
15255949   Curated Info

420

Altomare DA, et al. (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853-7
15208673   Curated Info

421

Chen G, et al. (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18, 1162-4
15132987   Curated Info

422

Liao X, et al. (2004) Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145, 2941-9
14988390   Curated Info

423

Hashimoto T, et al. (2004) Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 64, 3344-9
15126379   Curated Info

424

Ho L, et al. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-4
15033922   Curated Info

425

Kumar AS, et al. (2004) ILKAP regulates ILK signaling and inhibits anchorage-independent growth. Oncogene 23, 3454-61
14990992   Curated Info

426

Zhang F, et al. (2004) Adenovirus E4 gene promotes selective endothelial cell survival and angiogenesis via activation of the vascular endothelial-cadherin/Akt signaling pathway. J Biol Chem 279, 11760-6
14660586   Curated Info

427

Qu L, et al. (2004) Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev 18, 261-77
14744935   Curated Info

428

Emamian ES, et al. (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36, 131-7
14745448   Curated Info

429

Fan G, Ballou LM, Lin RZ (2003) Phospholipase C-independent activation of glycogen synthase kinase-3beta and C-terminal Src kinase by Galphaq. J Biol Chem 278, 52432-6
14561750   Curated Info

430

Bijur GN, Jope RS (2003) Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J Neurochem 87, 1427-35
14713298   Curated Info

431

Xu W, et al. (2003) The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 63, 7777-84
14633703   Curated Info

432

Salas TR, et al. (2003) Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278, 41338-46
12900420   Curated Info

433

Demarchi F, Bertoli C, Sandy P, Schneider C (2003) Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 278, 39583-90
12871932   Curated Info

434

Barry FA, Graham GJ, Fry MJ, Gibbins JM (2003) Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett 553, 173-8
14550568   Curated Info

435

Koivisto L, et al. (2003) Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytes. J Cell Sci 116, 3749-60
12890758   Curated Info

436

Li Y, et al. (2003) Morphine induces desensitization of insulin receptor signaling. Mol Cell Biol 23, 6255-66
12917346   Curated Info

437

Mottet D, et al. (2003) Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 278, 31277-85
12764143   Curated Info

438

Troussard AA, et al. (2003) Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278, 22374-8
12686550   Curated Info

439

Cruet-Hennequart S, et al. (2003) alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22, 1688-702
12642872   Curated Info

440

Asakuma J, et al. (2003) Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63, 1365-70
12649200   Curated Info

441

Takahashi-Yanaga F, et al. (2003) Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3beta and degrades cyclin D1 in mammalian cells. J Biol Chem 278, 9663-70
12522140   Curated Info

442

Song L, De Sarno P, Jope RS (2002) Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 277, 44701-8
12228224   Curated Info

443

Loberg RD, Vesely E, Brosius FC (2002) Enhanced glycogen synthase kinase-3beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J Biol Chem 277, 41667-73
12200436   Curated Info

444

Kim HS, et al. (2002) Regulation of angiogenesis by glycogen synthase kinase-3beta. J Biol Chem 277, 41888-96
12167628   Curated Info

445

Scheid MP, Marignani PA, Woodgett JR (2002) Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22, 6247-60
12167717   Curated Info

446

Baudhuin LM, Cristina KL, Lu J, Xu Y (2002) Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol Pharmacol 62, 660-71
12181443   Curated Info

447

Huang D, Cheung AT, Parsons JT, Bryer-Ash M (2002) Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes. J Biol Chem 277, 18151-60
11809746   Curated Info

448

Smith E, Coetzee GA, Frenkel B (2002) Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3beta. J Biol Chem 277, 18191-7
11877389   Curated Info

449

Dai F, et al. (2002) Human serum and glucocorticoid-inducible kinase-like kinase (SGKL) phosphorylates glycogen syntheses kinase 3 beta (GSK-3beta) at serine-9 through direct interaction. Biochem Biophys Res Commun 293, 1191-6
12054501   Curated Info

450

Eickholt BJ, Walsh FS, Doherty P (2002) An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. J Cell Biol 157, 211-7
11956225   Curated Info

451

Fang X, et al. (2002) Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22, 2099-110
11884598   Curated Info

452

Rössig L, et al. (2002) Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 277, 9684-9
11779850   Curated Info

453

Wang XQ, Sun P, Paller AS (2001) Inhibition of integrin-linked kinase/protein kinase B/Akt signaling: mechanism for ganglioside-induced apoptosis. J Biol Chem 276, 44504-11
11577096   Curated Info

454

Bijur GN, Jope RS (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276, 37436-42
11495916   Curated Info

455

O'toole A, Moule SK, Lockyer PJ, Halestrap AP (2001) Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308. Biochem J 359, 119-27
11563975   Curated Info

456

Somervaille TC, Linch DC, Khwaja A (2001) Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood 98, 1374-81
11520785   Curated Info

457

Grimes CA, Jope RS (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 78, 1219-32
11579131   Curated Info

458

De Mesquita DD, Zhan Q, Crossley L, Badwey JA (2001) p90-RSK and Akt may promote rapid phosphorylation/inactivation of glycogen synthase kinase 3 in chemoattractant-stimulated neutrophils. FEBS Lett 502, 84-8
11583116   Curated Info

459

Tang Q, Gonzales M, Inoue H, Bowden GT (2001) Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res 61, 4329-32
11389054   Curated Info

460

Harris MB, et al. (2001) Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 276, 16587-91
11340086   Curated Info

461

Leung-Hagesteijn C, Mahendra A, Naruszewicz I, Hannigan GE (2001) Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin-linked kinase, ILK1. EMBO J 20, 2160-70
11331582   Curated Info

462

Monick MM, et al. (2001) Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J Immunol 166, 4713-20
11254732   Curated Info

463

Chen EY, Mazure NM, Cooper JA, Giaccia AJ (2001) Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 61, 2429-33
11289110   Curated Info

464

Fang X, et al. (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97, 11960-5
11035810   Curated Info

465

Persad S, et al. (2000) Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A 97, 3207-12
10716737   Curated Info

466

Polakiewicz RD, et al. (1998) mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J Biol Chem 273, 23534-41
9722592   Curated Info